Key Drivers
- Strong Liquidity
- Thin Profitability
- Rich Valuation
AIAI Summary
PCRX now looks more investable as a focused EXPAREL franchise with improved outpatient reimbursement and a cleaner post-iovera business, but the stock already prices in a favorable execution path, so upside depends on clear revenue acceleration to validate the re-rating amid lingering valuation, leverage, and execution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Thin Profitability
- •Rich Valuation
PCRX has strong liquidity and cash generation with solid margins, but leverage, weak asset efficiency, and a premium valuation limit its appeal.
Price Behavior
Key Price Behavior Insights:
- •Breakout strength
- •Higher lows
- •Resistance test
Over the last month, PCRX broke above mid-23 resistance, has formed higher lows, and remains constructive while holding the mid-24s to $25.0, though $25.4 is a near-term hurdle and the quick run looks stretched.
Sharp breakout above prior resistance and a quick run-up suggest short-term stretch risk
Sentiment & News
Key News Insights:
- •Portfolio refocus
- •EXPAREL access
- •Shareholder backing
Pacira is sharpening its focus on non-opioid pain care by selling iovera°, securing separate EXPAREL reimbursement from UnitedHealthcare, and reinforcing shareholder support for its core strategy.
The updates are modestly positive for Pacira, as they streamline the portfolio and may expand demand for its core pain-management franchise
Similar Companies in Healthcare
Other companies in the same sector with AI ratings